TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.07 Million EUR | -96.9% |
| 2022 | -548 Thousand EUR | 92.19% |
| 2021 | -7.01 Million EUR | 31.45% |
| 2020 | -10.23 Million EUR | -705.27% |
| 2019 | -1.27 Million EUR | -355.73% |
| 2018 | 497 Thousand EUR | -74.94% |
| 2017 | 1.98 Million EUR | 172.76% |
| 2016 | 727 Thousand EUR | -84.81% |
| 2015 | 4.78 Million EUR | -0.1% |
| 2014 | 4.79 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.58 Million EUR | 0.0% |
| 2023 FY | -1.07 Million EUR | -96.9% |
| 2023 Q4 | -1.07 Million EUR | 5.76% |
| 2023 Q3 | -1.14 Million EUR | -68.88% |
| 2023 Q1 | -796 Thousand EUR | -45.26% |
| 2023 Q2 | -678 Thousand EUR | 14.82% |
| 2022 Q3 | -660 Thousand EUR | 89.22% |
| 2022 Q1 | -6.28 Million EUR | 10.4% |
| 2022 Q2 | -6.12 Million EUR | 2.64% |
| 2022 FY | -548 Thousand EUR | 92.19% |
| 2022 Q4 | -548 Thousand EUR | 16.97% |
| 2021 Q2 | -13.62 Million EUR | 0.33% |
| 2021 Q1 | -13.67 Million EUR | -33.56% |
| 2021 Q4 | -7.01 Million EUR | 0.3% |
| 2021 FY | -7.01 Million EUR | 31.45% |
| 2021 Q3 | -7.03 Million EUR | 48.35% |
| 2020 Q4 | -10.23 Million EUR | -5.53% |
| 2020 FY | -10.23 Million EUR | -705.27% |
| 2020 Q2 | -6.07 Million EUR | -0.16% |
| 2020 Q1 | -6.06 Million EUR | -377.5% |
| 2020 Q3 | -9.69 Million EUR | -59.55% |
| 2019 Q4 | -1.27 Million EUR | 2.31% |
| 2019 FY | -1.27 Million EUR | -355.73% |
| 2019 Q3 | -1.3 Million EUR | 11.01% |
| 2019 Q2 | -1.46 Million EUR | 2.27% |
| 2019 Q1 | -1.49 Million EUR | -401.01% |
| 2018 Q3 | -4.2 Million EUR | -311.84% |
| 2018 Q4 | 497 Thousand EUR | 111.82% |
| 2018 FY | 497 Thousand EUR | -74.94% |
| 2018 Q1 | 1.98 Million EUR | 0.05% |
| 2018 Q2 | 1.98 Million EUR | 0.0% |
| 2017 Q3 | 1.98 Million EUR | 349.66% |
| 2017 FY | 1.98 Million EUR | 172.76% |
| 2017 Q1 | 441 Thousand EUR | -39.34% |
| 2017 Q2 | 441 Thousand EUR | 0.0% |
| 2017 Q4 | 1.98 Million EUR | 0.0% |
| 2016 Q1 | 9.26 Million EUR | 93.57% |
| 2016 Q3 | 727 Thousand EUR | -92.15% |
| 2016 Q4 | 727 Thousand EUR | 0.0% |
| 2016 FY | 727 Thousand EUR | -84.81% |
| 2016 Q2 | 9.26 Million EUR | 0.0% |
| 2015 FY | 4.78 Million EUR | -0.1% |
| 2015 Q4 | 4.78 Million EUR | 0.0% |
| 2015 Q3 | 4.78 Million EUR | 0.0% |
| 2015 Q1 | 1.52 Million EUR | 0.0% |
| 2014 FY | 4.79 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -51.12% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 99.451% |
| Adocia SA | 127 Thousand EUR | 949.606% |
| Aelis Farma SA | -16.19 Million EUR | 93.336% |
| Biophytis S.A. | 2.7 Million EUR | 139.919% |
| Advicenne S.A. | 12.17 Million EUR | 108.862% |
| genOway Société anonyme | 2.97 Million EUR | 136.294% |
| IntegraGen SA | -709.74 Thousand EUR | -52.026% |
| Medesis Pharma S.A. | 1.15 Million EUR | 193.161% |
| Neovacs S.A. | -237.08 Thousand EUR | -355.107% |
| NFL Biosciences SA | -2.27 Million EUR | 52.59% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 124.768% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -29.914% |
| Sensorion SA | 1.37 Million EUR | 178.289% |
| Theranexus Société Anonyme | 2.44 Million EUR | 144.146% |
| Valbiotis SA | -18.13 Million EUR | 94.051% |
| TheraVet SA | 12.78 Thousand EUR | 8539.578% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 149.495% |
| argenx SE | -1.83 Billion EUR | 99.941% |
| BioSenic S.A. | 28.04 Million EUR | 103.848% |
| Celyad Oncology SA | -6.1 Million EUR | 82.317% |
| DBV Technologies S.A. | -114.95 Million USD | 99.061% |
| Galapagos NV | -157.2 Million EUR | 99.314% |
| Genfit S.A. | -7.61 Million EUR | 85.823% |
| GeNeuro SA | 5.91 Million EUR | 118.256% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 95.703% |
| Innate Pharma S.A. | -30.71 Million EUR | 96.487% |
| Inventiva S.A. | 10.48 Million EUR | 110.287% |
| MaaT Pharma SA | -10.2 Million EUR | 89.427% |
| MedinCell S.A. | 39.5 Million EUR | 102.732% |
| Nanobiotix S.A. | -24.71 Million EUR | 95.635% |
| Onward Medical N.V. | -12.89 Million EUR | 91.632% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 175.437% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 103.977% |
| Oxurion NV | 10.71 Million EUR | 110.075% |
| Pharming Group N.V. | 99.4 Million EUR | 101.085% |
| Poxel S.A. | 44.55 Million EUR | 102.422% |
| GenSight Biologics S.A. | 16.29 Million EUR | 106.622% |
| Transgene SA | -14.4 Million EUR | 92.512% |
| Financière de Tubize SA | 78.62 Million EUR | 101.372% |
| UCB SA | 2.17 Billion EUR | 100.05% |
| Valneva SE | 82.73 Million EUR | 101.304% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 94.175% |